Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2469602 | 0.78 | ALDH1A1 (0.38) | ALDH1A1LMNAHTTTSHRMAPT | |
| SCHEMBL1700018 | 0.77 | ALDH1A1 (0.36) | ALDH1A1LMNAHTTTSHRMAPT | |
| SCHEMBL14251019 | 0.77 | ALDH1A1 (0.36) | ALDH1A1LMNAHTTTSHRMAPT | |
| SCHEMBL7056602 | 0.67 | ALDH1A1 (0.38) | ALDH1A1LMNAHTTTSHRMAPT | |
| SCHEMBL12489209 | 0.67 | ALDH1A1 (0.38) | ALDH1A1LMNAHTTTSHRMAPT | |
| SCHEMBL18898921 | 0.64 | ALDH1A1 (0.34) | ALDH1A1LMNAHTTTSHRMAPT | |
| SCHEMBL16516842 | 0.62 | APLNR (0.33) | ALDH1A1TSHRMAPTPOLB | |
| SCHEMBL7280007 | 0.59 | ALDH1A1 (0.38) | ALDH1A1LMNATSHRMAPTKMT2A | |
| SCHEMBL21434917 | 0.58 | APLNR (0.52) | ALDH1A1LMNATSHRMAPTPOLB | |
| SCHEMBL21434918 | 0.58 | APLNR (0.52) | ALDH1A1LMNATSHRMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| EP-2202232-A1 | 1,2,4-oxadiazole derivatives and their therapeutic use | Laboratorios Almirall, S.A. (ES) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | ALDH1A1 1042/4885LMNA 3702/4885HTT 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.